Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Total Non-Current Liabilities (2017 - 2025)

Historic Total Non-Current Liabilities for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $407.7 million.

  • Cartesian Therapeutics' Total Non-Current Liabilities fell 960.19% to $407.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $407.7 million, marking a year-over-year decrease of 960.19%. This contributed to the annual value of $438.0 million for FY2024, which is 6.78% down from last year.
  • According to the latest figures from Q3 2025, Cartesian Therapeutics' Total Non-Current Liabilities is $407.7 million, which was down 960.19% from $390.1 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Total Non-Current Liabilities registered a high of $451.0 million during Q3 2024, and its lowest value of $32.6 million during Q3 2023.
  • For the 5-year period, Cartesian Therapeutics' Total Non-Current Liabilities averaged around $231.5 million, with its median value being $145.8 million (2021).
  • As far as peak fluctuations go, Cartesian Therapeutics' Total Non-Current Liabilities crashed by 5894.07% in 2022, and later surged by 128275.89% in 2024.
  • Cartesian Therapeutics' Total Non-Current Liabilities (Quarter) stood at $111.9 million in 2021, then plummeted by 52.73% to $52.9 million in 2022, then surged by 728.24% to $438.3 million in 2023, then dropped by 0.07% to $438.0 million in 2024, then decreased by 6.92% to $407.7 million in 2025.
  • Its last three reported values are $407.7 million in Q3 2025, $390.1 million for Q2 2025, and $428.9 million during Q1 2025.